Merck Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Merck wird ein jährliches Gewinn- und Umsatzwachstum von 14.5% bzw. 5.3% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 40.5% betragen.

Wichtige Informationen

14.4%

Wachstumsrate der Gewinne

14.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	5.3%
Zukünftige Eigenkapitalrendite	40.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	27 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Recent updates

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Aug 01

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Jul 31

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Jul 24

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Jul 18

Merck: Positive Developments, But Watch The Q2 Earnings

Jul 12

Merck: Among The Best Health Care GARP Plays Today

Jul 03

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Jun 30

Gewinn- und Umsatzwachstumsprognosen

NYSE:MRK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	72,612	25,668	25,838	29,688	22
12/31/2025	68,522	22,854	23,505	27,020	24
12/31/2024	64,122	18,812	18,830	23,866	24
6/30/2024	62,480	13,736	13,147	16,690	N/A
3/31/2024	61,403	2,306	11,040	14,757	N/A
12/31/2023	60,115	365	9,143	13,006	N/A
9/30/2023	59,314	4,608	13,167	17,190	N/A
6/30/2023	58,311	3,111	10,828	15,075	N/A
3/31/2023	57,869	13,030	11,262	15,673	N/A
12/31/2022	59,283	14,519	14,707	19,095	N/A
9/30/2022	58,974	15,322	15,249	19,696	N/A
6/30/2022	57,169	16,641	14,398	18,891	N/A
3/31/2022	53,978	13,910	12,870	17,220	N/A
12/31/2021	48,704	12,345	9,661	14,109	N/A
9/30/2021	46,131	5,908	8,401	13,072	N/A
6/30/2021	43,906	3,665	6,953	11,897	N/A
3/31/2021	41,857	4,793	6,659	11,184	N/A
12/31/2020	41,518	4,519	5,812	10,241	N/A
9/30/2020	42,438	9,492	6,906	11,041	N/A
6/30/2020	43,906	9,070	7,996	11,645	N/A
3/31/2020	46,312	9,399	8,947	12,811	N/A
12/31/2019	39,121	5,690	10,071	13,440	N/A
9/30/2019	45,970	9,314	8,973	12,238	N/A
6/30/2019	44,367	9,362	7,846	10,805	N/A
3/31/2019	43,073	8,399	8,343	11,103	N/A
12/31/2018	42,294	6,220	8,307	10,922	N/A
9/30/2018	41,729	3,347	8,948	11,349	N/A
6/30/2018	41,259	1,341	5,196	7,385	N/A
3/31/2018	40,725	1,579	N/A	7,320	N/A
12/31/2017	40,122	2,394	N/A	6,451	N/A
9/30/2017	39,804	2,845	N/A	6,064	N/A
6/30/2017	40,016	5,086	N/A	10,206	N/A
3/31/2017	39,929	4,346	N/A	8,489	N/A
12/31/2016	39,807	3,920	N/A	10,376	N/A
9/30/2016	39,907	5,492	N/A	10,990	N/A
6/30/2016	39,444	5,133	N/A	11,330	N/A
3/31/2016	39,385	4,614	N/A	12,427	N/A
12/31/2015	39,498	4,442	N/A	12,538	N/A
9/30/2015	39,765	10,781	N/A	7,128	N/A
6/30/2015	40,249	9,850	N/A	8,165	N/A
3/31/2015	41,398	11,168	N/A	7,783	N/A
12/31/2014	42,237	11,920	N/A	7,989	N/A
9/30/2014	43,075	5,385	N/A	12,050	N/A
6/30/2014	43,550	5,614	N/A	11,651	N/A
3/31/2014	43,626	4,516	N/A	11,674	N/A
12/31/2013	44,033	4,404	N/A	11,654	N/A
9/30/2013	44,450	4,531	N/A	10,437	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: MRKDas prognostizierte Gewinnwachstum (23.7% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: MRKDie Erträge des Unternehmens (14.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (14.9% pro Jahr).

Hohe Wachstumserträge: MRKDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: MRKDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: MRKDie Einnahmen des Unternehmens (5.3% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: MRKDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (39.8%)

Merck Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Recent updates

FDA Approves Merck's KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma

Merck Announces Overall Survival Results from the Final Analysis of the Phase 3 Keynote-811 Trial Evaluating Keytruda® (Pembrolizumab)

Merck Appears Ready To Return To June Highs (Technical Analysis)

Upcoming dividend of US$0.77 per share

Merck Announces WINREVAIR (Sotatercept) Is Authorized for Use in Canada for Adults with Pulmonary Arterial Hypertension

Merck & Co., Inc. and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™? for the Treatment of Diabetic Macular Edema

European Commission Approves Merck's KEYTRUDA (Pembrolizumab) Plus Padcev (Enfortumab Vedotin-Ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults

Merck's Change To Profit Guidance Provides An Opportunity

Merck & Co., Inc. Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials

Merck Receives European Commission Approval for Winrevair (Sotatercept) in Combination with Other Pulmonary Arterial Hypertension (Pah) Therapies, for the Treatment of Pah in Adult Patients with Functional Class II-III

Health Canada Approves Merck's KEYTRUDA® for the Treatment of Adult Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer with No Prior Systemic Therapy for mUC, in Combination with Enfortumab Vedotin

Merck: Buy This Bargain Before It's Gone

Merck & Co., Inc. Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer

Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Merck & Co., Inc. Revises Earnings Guidance for the Year 2024

Insufficient new directors

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins

Merck Receives Positive Eu Chmp Opinion for Keytruda® (Pembrolizumab) PPlus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma

First quarter dividend of US$0.77 announced

Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE

Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants

Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet

Merck & Co., Inc. (NYSE:MRK) completed the acquisition of Eyebiotech Limited.

Merck: Positive Developments, But Watch The Q2 Earnings

Merck & Co., Inc.(NYSE:MRK) dropped from Russell 3000E Value Index

Merck: Among The Best Health Care GARP Plays Today

What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken